Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab + Domvanalimab and Neoadjuvant Chemotherapy in Gastroesophageal Adenocarcinoma
NCT07283848Phase 2Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2026
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zimberelimab, domvanalimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Massachusetts General Hospital. Planned start Feb 2026; status: withdrawn.
02
Drugs
zimberelimabdomvanalimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07283848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07283848.